Effect of pimobendan on the clinical outcome and survival of cats with non-taurine responsive dilated cardiomyopathy.
Lydia E Hambrook, Peter F Bennett
Index: J. Feline Med. Surg. 14(4) , 233-9, (2012)
Full Text: HTML
Abstract
This retrospective study was designed to assess the effect of pimobendan on the median survival time (MST) of cats with non-taurine responsive dilated cardiomyopathy (DCM). Thirty-two client-owned cats with a left ventricular internal dimension at end systole (LVIDs) >14 mm, a fractional shortening (FS) <28% and a lack of response to taurine therapy were included over a 9-year period (2001-2010). These cats were divided into pimobendan (n=16) and non-pimobendan (n=16) treatment groups. All cats received standard treatment with frusemide, taurine and benazepril or enalapril. Nine cats in the non-pimobendan group also received digoxin. The MST of the pimobendan group (49 days; range 1 to >502 days) was four times that of the non-pimobendan group (12 days; 1 to 244 days). The difference in survival between the two groups was statistically significant (P = 0.048). Hypothermia and FS <20% were associated with a poor prognosis. No adverse effects to pimobendan were noted.
Related Compounds
Related Articles:
Synthesis, vasorelaxant activity and antihypertensive effect of benzo[d]imidazole derivatives.
2010-06-01
[Bioorg. Med. Chem. 18 , 3985-91, (2010)]
Valvular dysplasia and congestive heart failure in a juvenile African penguin (Spheniscus demersus).
2014-12-01
[J. Zoo Wildl. Med. 45(4) , 987-90, (2014)]
2015-06-01
[J. Cardiovasc. Pharmacol. 65(6) , 640-8, (2015)]
A review of the pharmacology and clinical uses of pimobendan.
2012-08-01
[J. Vet. Emerg. Crit. Care (San Antonio.) 22(4) , 398-408, (2012)]
In vitro effect of pimobendan on platelet aggregation in dogs.
2013-03-01
[Am. J. Vet. Res. 74(3) , 403-7, (2013)]